格隆汇6月6日|据欧洲药品监管机构称,服用诺和诺德(NVO.US)的Ozempic和Wegovy等减肥药的患者存在患上可能导致视力下降的眼部疾病的风险。欧洲药品管理局的安全委员会发现,一种名为NAION(非动脉炎性前部缺血性视神经病变)的眼病是西马鲁肽的“非常罕见”副作用,西马鲁肽是糖尿病和减肥药的关键成分。 该机构周五表示,每1万名服用这些药物的人中就有1人会受到影响,现在必须更新产品标签。丹麦...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.